Loading...
Market
What regulatory hurdles will Roche face in acquiring Poseida by December 31, 2025?
2
Resolution / Starting Odds
No major hurdles • 25%
Minor delays • 25%
Significant delays • 25%
Acquisition blocked • 25%
Reports from financial analysts, regulatory filings, or official statements from Roche
Story
Roche to Acquire Poseida Therapeutics for $9 Per Share Plus $4 CVR in $1.5 Billion CAR-T Deal
Nov 26, 2024, 06:45 AM
Roche Holding AG has entered into a definitive agreement to acquire California-based Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company specializing in CAR-T cell therapies, for $9 per share in cash, totaling $1 billion upfront. Shareholders will also receive a non-tradeable contingent value right (CVR) of up to $4 per share, bringing the total potential value of the deal to $1.5 billion. This transaction represents a significant premium of approximately 200% over Poseida's recent share price. The acquisition includes Poseida's cell therapy candidates and related platform technologies, which focus on developing off-the-shelf CAR-T therapies for the treatment of autoimmune diseases, hematological malignancies, and solid tumors.
View original story
Similar markets
Full $1.5 billion • 25%
$1.25 - $1.5 billion • 25%
$1 - $1.25 billion • 25%
Below $1 billion • 25%
FDA (US) • 25%
EMA (Europe) • 25%
NMPA (China) • 25%
Other • 25%
EU appeals ruling • 25%
Illumina submits new bid • 25%
No further action • 25%
Other • 25%
Yes • 50%
No • 50%
FDA approval • 25%
FDA rejection • 25%
Conditional approval • 25%
No decision • 25%
European Commission • 25%
U.S. Federal Trade Commission • 25%
China's State Administration for Market Regulation • 25%
Other • 25%
Yes • 50%
No • 50%
